stockrowIonis Pharmaceuticals, Inc.
IONS Healthcare Biotechnology
Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024.
- Revenue
- −40.7%
- EPS
- −188.5%
- Free cash flow
- +299.3%
- Total debt
- +116.0%
Quarter to June 2026, against a year earlier
Follow IONS
Alert me
Ionis Pharmaceuticals, Inc. (IONS) EBITDA
Ionis Pharmaceuticals, Inc.'s EBITDA for fiscal 2025 was −$375.8M, compared with −$484.1M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$579.9M. Over the past ten years it has ranged from −$484.1M (fiscal 2024) to $377.3M (fiscal 2019); the current reading is higher than 18% of that period. Ionis Pharmaceuticals, Inc. ranks 584th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$375.8M | — |
| FY2024 | −$484.1M | — |
| FY2023 | −$353.8M | — |
| FY2022 | −$375.3M | — |
| FY2021 | $12.1M | — |
| FY2020 | −$140.1M | — |
| FY2019 | $377.3M | — |
| FY2018 | −$14.7M | — |
| FY2017 | $82.3M | 199.49% |
| FY2016 | $27.5M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$96.2M | — |
| Mar 2026 | −$113.8M | — |
| Dec 2025 | −$210.8M | — |
| Sep 2025 | −$159.1M | — |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | $57.3M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$118.6M |
| AXSM Axsome Therapeutics, Inc. compare | −$139.8M |
| ORKA Oruka Therapeutics, Inc. compare | −$158.0M |
| KOD Kodiak Sciences Inc. compare | −$220.8M |
| CGON CG Oncology, Inc. compare | −$250.7M |
| IMVT Immunovant, Inc. compare | −$565.6M |
| IONS Ionis Pharmaceuticals, Inc. | −$579.9M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$867.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on IONS
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement